Artigo Revisado por pares

Therapeutic Monitoring of Psychotropic Drugs

2004; Lippincott Williams & Wilkins; Volume: 26; Issue: 2 Linguagem: Inglês

10.1097/00007691-200404000-00014

ISSN

1536-3694

Autores

Pierre Baumann, Christoph Hiemke, S. Ulrich, I. Gaertner, M. L. Rao, Gabriel Eckermann, M. Gerlach, Hans‐Joachim Kuss, G. Laux, B. Müller‐Oerlinghausen, Peter Riederer, Gerald Zernig,

Tópico(s)

Pharmacological Effects and Toxicity Studies

Resumo

TDM of psychotropic drugs is widely used, but there is little consensus regarding its optimal use in the clinical context. This prompted a multidisciplinary group comprised of clinical biochemists, clinical pharmacologists, and psychiatrists of the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) to provide a consensus guideline. This will allow clinical psychiatrists, practitioners, and laboratory directors involved in psychopharmacotherapy to optimize TDM of antidepressants, antipsychotics, and opioid substituents. Recommendations are also given on the combined use of TDM and pharmacogenetic tests.

Referência(s)